Condition
Dyskinesias
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 28 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
28 shownReliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)NCT07023224 · 2024-11-14
RECRUITINGClinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated DystoniaNCT05317390 · 2022-06-01
RECRUITINGConnectomic Guided DBS for Parkinson's DiseaseNCT06618157 · 2026-02-16
ENROLLING_BY_INVITATIONOpen-Label Extension Study of ASTORIANCT05516875 · 2024-01-19
TERMINATEDOpen-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based TherapyNCT05116813 · 2021-10-25
TERMINATEDRandomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced DyskinesiaNCT04912115 · 2021-10-05
SUSPENDEDEffects of Music Beat on Motor Function in Individuals At Risk for Psychotic Onset and Schizophrenia PatientsNCT04929795 · 2021-08-11
COMPLETEDDipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based TherapyNCT04857359 · 2021-08-06
TERMINATEDStudy in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual ComponentsNCT04377945 · 2021-04-28
TERMINATEDEffects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia PatientsNCT04553835 · 2020-08-31
UNKNOWNEffects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic OnsetNCT04086160 · 2019-08-22
UNKNOWNA Study in Parkinson's Disease in Patients With Moderate to Severe DyskinesiaNCT03956979 · 2019-07-22
COMPLETEDA Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's DiseaseNCT04453995 · 2019-01-05
UNKNOWNAn Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseNCT03034538 · 2016-04-08
SUSPENDEDBuspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaNCT02589340 · 2016-01-01
TERMINATEDEvaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasNCT01491529 · 2012-04-01
COMPLETEDOpen-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasNCT01491932 · 2012-03-01
COMPLETEDEvaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasNCT01385592 · 2011-11-01
COMPLETEDSafety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseNCT01474421 · 2011-09-15
COMPLETEDEvaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseNCT00986414 · 2009-09-01
COMPLETEDSafety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's SubjectsNCT00360568 · 2009-06-01
COMPLETEDDifferent Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsNCT00888186 · 2008-02-01
COMPLETEDEffects of Talampanel on Patients With Advanced Parkinson's DiseaseNCT00036296 · 2006-12-01
COMPLETEDDeveloping Objective Measures of Levodopa Induced Dyskinesia: (Study 1)NCT00467597 · 2006-04-01
COMPLETEDACP-103 to Treat Parkinson's DiseaseNCT00086294 · 2004-06-25
COMPLETEDLevetiracetam Treatment of L-dopa Induced DyskinesiasNCT00076674 · 2004-01-01
COMPLETEDOnset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson'sNCT00363727 · 2003-12-01
COMPLETEDStudy of LY300164 for the Treatment of Parkinson's DiseaseNCT00004576 · 2000-02-01
COMPLETEDCommon interventions
PlaceboDRUG6AFQ056DRUG4DipraglurantDRUG2Intravenous LevodopaDRUG2ACP-103DRUG1AQW051DRUG1BuspironeDRUG1CADD-Legacy® 1400 ambulatory infusion pumpDEVICE1Cerebellothalamic optimized deep brain stimulationDEVICE1DystoniaNet-based diagnosis of isolated dystoniaDIAGNOSTIC_TEST1J-tubeDEVICE1JM-010DRUG1JM-010 group ADRUG1JM-010 group BDRUG1KetamineDRUG1Levodopa (delivered intravenously)DRUG1Levodopa-carbidopa intestinal gelDRUG1levodopa/carbidopaDRUG1LY300164DRUG1MidazolamDRUG1No deep brain stimulationOTHER1no RASBEHAVIORAL1No RAS for at-risk individualsBEHAVIORAL1No RAS for schizophrenia patientsBEHAVIORAL1Pallidothalamic optimized deep brain stimulationDEVICE1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Novartis Pharmaceuticals
4
Dr WANG Shumei
3
National Institute of Neurological Disorders and Stroke (NINDS)
3
Addex Pharma S.A.
2
AbbVie (prior sponsor, Abbott)
1
Bukwang Pharmaceutical
1
Contera Pharma
1
Contera Pharma A/S
1
Duke University
1
GlaxoSmithKline
1
Izmir Bakircay University
1
Massachusetts Eye and Ear Infirmary
1
Novartis
1
Oregon Health and Science University
1
PharmaTher Inc.
1
Trial status mix
COMPLETED15
TERMINATED5
UNKNOWN3
RECRUITING2
SUSPENDED2
ENROLLING_BY_INVITATION1
Phase mix
PHASE215
NA5
PHASE34
PHASE12
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.